Maurizio Acampa

Jul 13, 2024 | mdpi.com | Maurizio Acampa |Pietro Lazzerini |Alessandra Cartocci |Ernesto Iadanza

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 10, 2023 | frontiersin.org | Karina Carvalho |Maurizio Acampa |Cristina Tudoran

1. Introduction Long COVID Syndrome, know as Long COVID, can be described as the persistence signs and symptoms that continue or develop for more than 4 weeks after acute COVID-19 infection (1). During clinical evaluation, differential diagnosis and the identification of associated pathologies unrelated to SARS-CoV-2 infection are essential (2). Manifestations of Long COVID occur in approximately 50%–80% of previously symptomatic patients with COVID-19 who have recovered (3).

Jul 4, 2023 | frontiersin.org | Maurizio Acampa

Orthostatic intolerance (OI) is a form of autonomic nervous system (ANS) disturbance characterized by orthostatic dysregulation and a wide variety of ANS symptoms, accompanied by cognitive and psychological issues (Raj et al., 2018). While it typically appears in adolescence, recent reports have shown increasing morbidity as a sequela of COVID-19 (van Campen et al., 2022). Nevertheless, these conditions have not received attention.

Jun 9, 2023 | frontiersin.org | Maurizio Acampa |Manon Kappelhof |Zhenhui Duan

1 IntroductionIn 2015, results from five randomized controlled trials (RCT) established endovascular therapy (EVT) as the optimal treatment for acute ischemic stroke (AIS) involving large vessel occlusion (LVO), provided that it was performed within an effective time window. Specifically, the MR CLEAN, EXTEND-IA, and SWIFT PRIM trials were conducted within 6 h of stroke onset (1–3), while the REVASCAT trial was conducted within 8 h (4), and the ESCAPE trial within 12 h (5).